Navigation Links
Biomarker May Predict Response to Cancer Therapy
Date:4/13/2008

Dutch researchers identify cell type that is potential target for these agents

SUNDAY, April 13 (HealthDay News) -- A biomarker that may help doctors monitor the effectiveness of common treatments for kidney cancer and non-small cell lung cancer has been identified by researchers in the Netherlands.

The researchers found that CD34bright/CD133neg candidate circulating Endothelial Progenitor Cells (ccEPCs) are a potential biomarker during treatment with sunitinib (Sutent) or bevacizumab (Avastin).

"Our work provides novel data on a potential biomarker for the monitoring of anti-angiogenic drug activity in cancer patients, as well as identifies a cell type that is a potential target for these agents," Laura Vroling, a researcher in the department of medical oncology at VU University Medical Center in Amsterdam, said in a prepared statement.

Vroling and her colleagues noted that bevacizumab and sunitinib, which target the vascular endothelial growth factor (VEGF), have proven effective against a number of cancers, but doctors aren't able to determine which patients might derive the most benefit from these drugs.

"Therefore, it is of great importance to identify and validate biomarkers for early response or duration of response," Vroling said.

She and her team studied 23 patients with renal cell cancer and 19 patients with non-small cell lung cancer.

"In our study, for the first time, the behavior of two CD34bright cell populations, (CD45neg) candidate cEPcs and (CD45dim) HPCs (hematopoietic progenitor cells), were monitored and showed a different response of both cell populations during sunitinib or bevacizumab therapy. The role of ccEPCs in human tumor angiogenesis and their potential in prediction of treatment outcome of anti-VEGF therapy needs to be addressed in future, larger clinical cohorts," Vroling said.

The study findings were to be presented Sunday at the annual meeting of the American Association for Cancer Research, in San Diego.

More information

The National Academies Press has more about cancer biomarkers.



-- Robert Preidt



SOURCE: American Association for Cancer Research, news release, April 13, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Biomarkers may reduce need for biopsies
2. Scientists: New technique identifies molecular biomarkers for disease
3. Biomarker May Signal HIV Progression
4. Expansion of monocyte subset could serve as a biomarker for HIV progressions
5. Biomarkers and Innovation Push Global Cancer Diagnostics Market Toward $8 Billion
6. Biomarkers for Mood May Alter Psychiatric Treatments
7. UCLA researchers discover biomarkers that predict lung cancer patient response to therapy
8. Proteomic profiling shown more accurate than traditional biomarkers in identifying liver cancer
9. New developments in biomarkers for epithelial ovarian cancer
10. Biomarkers for Alzheimers disease can be trusted in clinical trials
11. JDRF and Lilly partner to fund research to identify beta cell biomarkers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: